Kiniksa Pharmaceuticals International plc. - Class A

Research Kiniksa Pharmaceuticals International plc. - Class A (KNSA) on Bullrun: valuation model: 31.2% overvalued, market cap USD 6.25B, P/E 81.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerKNSA
ExchangeNASDAQ
CountryUnited Kingdom
SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic
CurrencyUSD
Valuation signal31.2% overvalued
Market capUSD 6.25B
P/E81.5
Financial periodQ2 2026
RevenueUSD 243.60M
Net incomeUSD 25.43M
Free cash flowUSD 46.53M
Gross margin54.2%

Valuation Snapshot

Bullrun's latest valuation model marks Kiniksa Pharmaceuticals International plc. - Class A as 31.2% overvalued; latest market cap is USD 6.25B; P/E is 81.5.

Peer valuation comparison

Latest P/E is 81.55x versus a Healthcare sector median of 24.46x (233.4% above).

Latest P/E is 81.55x versus a United Kingdom median of 16.18x (404.1% above).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 677.56M	USD 59.01M	USD 136.42M	88.5%	0.75	USD 165.60M	USD 9.50M	USD 567.61M
FY2024	USD 423.24M	-USD 43.19M	USD 25.41M	85.6%	-0.6	USD 183.58M	USD 9.86M	USD 438.44M
FY2023	USD 270.26M	USD 14.08M	USD 13.17M	87.6%	0.2	USD 107.95M	USD 12.26M	USD 438.84M
FY2022	USD 220.18M	USD 183.36M	USD 5.70M	89.6%	2.6	USD 122.72M	USD 4.61M	USD 396.15M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-25	USD 6.25B	81.5	n/a	n/a
2025	2025-12-31	USD 3.15B	55.0	n/a	n/a
2024	2024-12-31	USD 1.43B	n/a	n/a	n/a
2023	2023-12-29	USD 1.23B	n/a	n/a	n/a
2022	2022-12-30	USD 1.04B	7.5	n/a	n/a
2021	2021-12-31	USD 812.84M	n/a	n/a	n/a

Company Brief

Kiniksa reported a 60.1% year-over-year revenue increase and achieved profitability with net income up 236.6%. The company is also advancing its pipeline by presenting upcoming data from clinical trials at investor conferences.

Revenue grew significantly to reach FY2025 levels, supported by gross margins expanding to 88.5% while the company transitioned into a profitable net income position.

Investors should monitor sales performance of ARCALYST and potential regulatory developments for KPL-387's Phase 2/3 trials.

Related stock research

United Kingdom stocks United Kingdom Healthcare stocks A-Z stock index

Other Healthcare stocks

Haleon PLC (H6D0) Haleon plc (HLN) Shield Therapeutics plc (1JS) IMMUPHARMA PLC LS-01 (25I) ConvaTec Group PLC (2CV) RENALYTIX PLC LS-0025 (2O9) KANABO GROUP PLC LS-025 (3WD) 4BASEBIO UK SOCIETAS (4BB) SKINBIO THERAP LS-01 (5KW) VERICI DX PLC LS-001 (63V) ARECOR THERAPEUTICS -01 (6UI) 4BASEBIO PLC EO 1 (88Q)

Frequently asked questions

Is Kiniksa Pharmaceuticals International plc. - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Kiniksa Pharmaceuticals International plc. - Class A as 31.2% overvalued.

What is Kiniksa Pharmaceuticals International plc. - Class A's market cap?

Kiniksa Pharmaceuticals International plc. - Class A's market capitalization is USD 6.25B.

What is Kiniksa Pharmaceuticals International plc. - Class A's P/E ratio?

Kiniksa Pharmaceuticals International plc. - Class A's price-to-earnings (P/E) ratio is 81.5.

What does Kiniksa Pharmaceuticals International plc. - Class A do?

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.